Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Immediate Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects

NCT03475706 is registered in ClinicalTrials.gov with Velicept Therapeutics, Inc. as lead sponsor.

NCT NCT03475706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03475706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Immediate Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects
Lead sponsor
Velicept Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2018
Completion date
January 30, 2019
Enrollment
438 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder